An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Immutep (ASX:IMM) has dosed the first patient in its pivotal Phase III trial evaluating eftilagimod alfa (efti) for the ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...